ILiAD Biotechnologies

ILiAD Biotechnologies, Inc. is a Delaware-incorporated clinical-stage biotechnology company founded in 2012, focused on the prevention and treatment of disease caused by Bordetella pertussis (whooping cough). Its lead candidate, BPZE1, is the world's most advanced next-generation pertussis vaccine — a live attenuated intranasal vaccine that has completed four Phase 2 clinical trials and demonstrated both efficacy and prevention of bacterial colonization. The company is based in Weston, Florida, and also operates BioLyo Technologies, BV, a wholly-owned CDMO subsidiary in Ghent, Belgium specializing in live bacterial product development. In 2026, ILiAD closed an oversubscribed $115M Series B to advance BPZE1 toward Phase 3.